tbuckley/cabot-search huggingface dataset:
Website of the Week: Chlamydia
Authors: Adrian Gonzalez
Journal: BMJ (2003)

Trying to find quality information online about a subject such as Chlamydia is not easy—a simple search in any web based engine throws up a lot of sites, but not a lot of useful ones. Pop-ups and the tons of information from drug companies can make your web experience miserable.

But there is often some hidden oasis. In the case of Chlamydia, the subject of a paper in this week's BMJ (p 1252), www.chlamydiae.com is an excellent site for the public and professionals alike. Visitors need to register, but the site is totally free. There is much here about any Chlamydia related topic, and the information has apparently been produced and peer reviewed by Chlamydia experts. This is undoubtedly the site for anyone wishing to know more about the Chlamydiae family. The site is also available in Arabic, Chinese, French, German, Italian, Japanese, Portuguese, Russian, Spanish, and Thai.

Good information about Chlamydia infection is often found on sites dealing with sexually transmitted infections in general. The World Health Organization has a page on the global prevalence and incidence of selected curable sexually transmitted infections (www.who.int/docstore/hiv/GRSTI/000.htm), which is useful for anyone trying to find data about the disease. The site provides information about Chlamydia in the most deprived regions in the world. However, the data is not that new—the most recent figures are from 1999.

Basic scientific information about the microbiology of the genitourinary system is available from the Graduate School of Biomedical Sciences at The University of Texas Medical Branch (http://gsbs.utmb.edu/microbook/ch097.htm). Information suitable for patients, in an easy to read format and with good explanations, is available from Planned Parenthood (www.plannedparenthood.org/STI-SAFESEX/chlamydia.htm).
ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Authors: Jordi Rodon, Mark Rosenthal, Warren Mason, Pedro Perez Segura, Joseph T. Beck, Holger Hirte, John F. DeGroot, Lucia Trandafir, Nathalie Pognan, Lin Yang, Charu Kanwal, Patrick Y. Wen
Journal: Neuro-Oncology (2015)

BACKGROUND: Phase I, two-stage study of buparlisib combined with standard-of-care (RT + TMZ followed by adjuvant TMZ) in newly diagnosed GBM. METHODS: Stage I evaluated buparlisib with adjuvant TMZ in 28-day treatment cycles after prior RT + TMZ treatment. Stage II evaluated buparlisib with concomitant RT + TMZ and then adjuvant TMZ. In the concomitant phase, buparlisib was administered at two schedules: 60mg/40mg/QD or 40mg D1–5/Q7, in combination with RT (2.5 Gy/day) + TMZ 75mg/m2/day over 42 days. In the adjuvant phase, buparlisib was administered at 80mg/QD during Cycle 1 with TMZ 150mg/m2 D1–D5/Q28 (A1), and at 60mg/80mg/QD during Cycles 2–12 with TMZ 200mg/m2 on D1–D5/Q28 (A2). Dose-escalation was guided by a Bayesian logistic regression model with overdose control principle. Primary study objectives were to identify buparlisib dose-limiting toxicities (DLTs) and to determine the recommended Phase II dose (RP2D). RESULTS: Adjuvant: Of 16 patients treated, six developed DLTs, including three DLTs in A1: Grade(G) 3-hyperglycemia, G3-anxiety, G3-intermittent confusion (1 patient each) at 80mg/QD; and three in A2: G2-hyperglycemia (1 patient) at 60mg/QD, G4-platelet count decrease and G4-thrombocytopenia (1 patient each) at 80mg/QD. Concomitant: Of 22 patients treated, seven developed DLTs: G4-thrombocytopenia (2 patients) at 60mg/QD, G4-lipase elevation (2 patients) and G2-thrombocytopenia (1 patient) at 40mg/QD, G3-decreased mood (1 patient) and G4-decreased platelet count (1 patient) at 40mg D1–5/Q7. Twenty-three patients (60.5%) experienced study-drug-related G3/4 adverse events (AEs) including hyperglycemia, neutropenia, thrombocytopenia (13.2% each), and lipase increase (10.5%). Twenty-nine patients discontinued treatment due to AEs (44.7%), disease progression (26.3%), and withdrawal of consent (5.3%). CONCLUSION: RP2D of buparlisib for the adjuvant phase in combination with TMZ was defined as 80mg/QD. RP2D of buparlisib plus RT + TMZ was not determined due to challenging safety at all doses/schedules. Exposure of buparlisib with RT + TMZ was slightly lower than that of single-agent buparlisib. Anti-tumor activity is under evaluation and will be reported.
Abstract P2-11-04: Serum IgG response against prostate-related antigen revealed by personalized peptide vaccination in patients with metastatic recurrent breast cancer
Authors: U Toh, M Okabe, N Iwakuma, M Mishima, S Shichijo, A Yamada, M Noguchi, K Itoh, Y Akagi
Journal: Cancer Research (2016)

Abstract Purpose: We have indicated that IgG and CTL boosting response could be a potential prognostic factor for overall survival (OS) and progression free survival (PFS) in metastatic recurrent breast cancer (mrBC) patients, who had received personalized selected peptide vaccine (PPV) therapy in our previously reported clinical phase II study. The aim of this study is to identify the prognostic role of serum value of IgG antibody against prostate related-antigen (PRA), including prostate-specific antigen (PSA), prostate specific membrane antigen (PSMA) and prostate acid phosphatase (PAP) in mrBC patients Methods: Peripheral blood samples of 77 patients with mrBC were analyzed for serum anti-PRA IgG levels before and after 6th and 12th PPV therapy prospectively. Most of the peptides using for PPV are derived from cancer associated antigens expressing in various types of advanced cancers, but the peptides derived from PRAs were not used in this study. Results: After PPV therapy, total serum levels of anti-PRA IgG were significantly increased in 31 mrBC patients (Group 1) whereas in remaining 46 rmBC patients (Group 2). Either serum anti-PSA, anti-PAP and/or anti-PMSA IgGs showed a significant increase in patients of Group 1 after 6th (p=0.045) and 12th PPV treatment (p &amp;lt; 0.001), irrespective of their intrinsic subtypes. The median PFS and median OS of Group 1 patients were 8.1 and 14.3 months, while those of Group 2 patients were 5.1 and 10.8 months, respectively. Anti-PRA IgG levels were significantly associated with PFS (p=0.0073; HR: 0.37) and OS (p=0.025; HR: 0.43) between these two groups, whereas no significant relation was found with age, clinical response rate and recurrent metastatic status. Conclusions: The Group 1 patients with elevated anti-PRA IgG may have better prognosis compared to Group 2 patients who showed no IgG elevation after PPV treatment for rmBC. These results indicated a clinical significance between pre-and post- treatment measurement of serum anti-PRA IgGs in mrBC patients receiving PPV therapy, and may be a useful prognostic marker for monitoring the outcome to PPV treatment of breast cancer. Citation Format: Toh U, Okabe M, Iwakuma N, Mishima M, Shichijo S, Yamada A, Noguchi M, Itoh K, Akagi Y. Serum IgG response against prostate-related antigen revealed by personalized peptide vaccination in patients with metastatic recurrent breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-04.
Growth Inhibition of Homografts of a Plasma-Cell Neoplasm in Cell-Impenetrable Diffusion Chambers Placed in Hyperimmunized Mice
Authors: Glenn H. Algire
Journal: JNCI Journal of the National Cancer Institute (1959)

Most of the homografts of the plasma-cell neoplasm 70429 grew, if they were placed in cell-impenetrable diffusion chambers in untreated mice or in mice that had received one immunizing dose, but most were destroyed or inhibitied in their growth, if placed in hyperimmunized hosts. Other homologous cells, however, transplanted into hyperimmunized hosts with the tumor cells, survived and grew. Thus, homografts of some, but not all, types of cells are destroyed or inhibited in their growth in hyperimmunized hosts, without the participation of host cells.
A critique of the St. Louis psychiatric research criteria for schizophrenia
Authors: M A Taylor, R Abrams
Journal: American Journal of Psychiatry (1975)

The authors reviewed the research data for 89 hospitalized patients who were given a diagnosis of schizophrenia and 22 who were given a diagnosis of mania on admission. They found that 11 (12 percent) of the schizophrenic patients satisfied the St. Louis research criteria for schizophrenia and 10 (11 percent) satisfied the authors' criteria. Diagnostic agreement between the sets of criteria was shared in only 5 of these patients. On the basis of this finding and other studies of the St. Louis criteria, the authors suggest specific modifications that would broaden the utility of these criteria and minimize diagnostic disagreement.
Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis
Authors: Toby O Smith, Kun Zou, Natasya Abdullah, Xi Chen, Sarah R Kingsbury, Michael Doherty, Weiya Zhang, Philip G Conaghan
Journal: Annals of the Rheumatic Diseases (2016)

Objectives It is thought that the clinical trial benefits of oral non-steroidal anti-inflammatory drugs (NSAIDs) may relate to flare designs. The aim of this study was to examine the difference in NSAID (including cyclooxygenase-2 (COX-2) inhibitors) response in osteoarthritis (OA) trials based on different designs. Methods Systematic review was undertaken of the databases MEDLINE, EMBASE, AMED, CINAHL and the Cochrane library till February 2015. Randomised controlled trials assessing pain, function and/or stiffness following commencement of NSAIDs in flare and non-flare designs were eligible. Trials were assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted to assess the effect sizes (ES) of NSAIDs for OA with flare versus non-flare trial designs. Results Fifty-seven studies including 33 263 participants assessing 26 NSAIDs were included. Twenty-two (39%) were flare design, 24 (42%) were non-flare designs, 11 (19%) were possible flare designs. On meta-analysis, there was no statistically significant difference in ES of NSAIDs versus placebo between flare and non-flare trial designs for absolute pain and function or stiffness at immediate-term (1 week), short-term (2–4 week) or longer-term (12–13 week) follow-up periods (p&gt;0.05). However there was a lower ES for mean change in pain in flare and possible flare trials compared with non-flare trials at short-term follow-up (0.36 vs 0.69; p=0.05). Conclusions Contrary to previous understanding, flare trial designs do not result in an increased treatment effect for NSAIDs in people with OA compared with non-flare design. Whether flare design influences other outcomes such as joint effusion remains unknown.
Adult Asthma
Authors: Janet M. Torpy
Journal: JAMA (2004)

Adult AsthmaA sthma is a common disease that involves inflammation (cellular injury) and narrowing of the airways leading to the lungs.Asthma occurs in children and adults.Childhood asthma may continue into adolescence and adulthood, but some adults who develop asthma did not have asthma when they were younger.Millions of people worldwide are affected by asthma, which has become more common in recent years.Asthma attacks cause significant disruptions to a person' s life, and severe asthma attacks can be fatal.The July 21, 2004, issue of JAMA includes an article about adult asthma.
Refinement of screening for familial pancreatic cancer
Authors: D K Bartsch, E P Slater, A Carrato, I S Ibrahim, C Guillen-Ponce, H F A Vasen, E Matthäi, J Earl, F S Jendryschek, J Figiel, M Steinkamp, A Ramaswamy, E Vázquez-Sequeiros, M Muñoz-Beltran, J Montans, E Mocci, B A Bonsing, M Wasser, G Klöppel, P Langer, V Fendrich, T M Gress
Journal: Gut (2016)

Surveillance programmes are recommended for individuals at risk (IAR) of familial pancreatic cancer (FPC) to detect early pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC). However, the age to begin screening and the optimal screening protocol remain to be determined.IAR from non-CDKN2A FPC families underwent annual screening by MRI with endoscopic ultrasonography (EUS) in board-approved prospective screening programmes at three tertiary referral centres. The diagnostic yield according to age and different screening protocols was analysed.253 IAR with a median age of 48 (25-81) years underwent screening with a median of 3 (1-11) screening visits during a median follow-up of 28 (1-152) months. 134 (53%) IAR revealed pancreatic lesions on imaging, mostly cystic (94%), on baseline or follow-up screening. Lesions were significantly more often identified in IAR above the age of 45 years (p<0.0001). In 21 IAR who underwent surgery, no significant lesions (PDAC, pancreatic intraepithelial neoplasia (PanIN) 3 lesions, high-grade intraductal papillary mucinous neoplasia (IPMN)) were detected before the age of 50 years. Potentially relevant lesions (multifocal PanIN2 lesions, low/moderate-grade branch-duct IPMNs) occurred also significantly more often after the age of 50 years (13 vs 2, p<0.0004). The diagnostic yield of potentially relevant lesions was not different between screening protocols using annual MRI with EUS (n=98) or annual MRI with EUS every 3rd year (n=198) and between IAR screened at intervals of 12 months (n=180) or IAR that decided to be screened at ≥24 months intervals (n=30).It appears safe to start screening for PDAC in IAR of non-CDKN2a FPC families at the age of 50 years. MRI-based screening supplemented by EUS at baseline and every 3rd year or when changes in MRI occur appears to be efficient.
A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles
Authors: Hao Zhou, Zhiyuan Fan, Pelin K. Lemons, Hao Cheng
Journal: Theranostics (2016)

Convenient strategies to provide cell membrane-coated nanoparticles (CM-NPs) with multi-functionalities beyond the natural function of cell membranes would dramatically expand the application of this emerging class of nanomaterials.We have developed a facile approach to functionalize CM-NPs by chemically modifying live cell membranes prior to CM-NP fabrication using a bifunctional linker, succinimidyl-[(N-maleimidopropionamido)-polyethyleneglycol] ester (NHS-PEG-Maleimide).This method is particularly suitable to conjugate large bioactive molecules such as proteins on cell membranes as it establishes a strong anchorage and enable the control of linker length, a critical parameter for maximizing the function of anchored proteins.As a proof of concept, we show the conjugation of human recombinant hyaluronidase, PH20 (rHuPH20) on red blood cell (RBC) membranes and demonstrate that long linker (MW: 3400) is superior to short linker (MW: 425) for maintaining enzyme activity, while minimizing the changes to cell membranes.When the modified membranes were fabricated into RBC membrane-coated nanoparticles (RBCM-NPs), the conjugated rHuPH20 can assist NP diffusion more efficiently than free rHuPH20 in matrix-mimicking gels and the pericellular hyaluronic acid matrix of PC3 prostate cancer cells.After quenching the unreacted chemical groups with polyethylene glycol, we demonstrated that the rHuPH20 modification does not reduce the ultra-long blood circulation time of RBCM-NPs.Therefore, this surface engineering approach provides a platform to functionlize CM-NPs without sacrificing the natural function of cell membranes.
Zika and the Risk of Microcephaly
Authors: Michael A. Johansson, Luis Mier-y-Teran-Romero, Jennita Reefhuis, Suzanne M. Gilboa, Susan L. Hills
Journal: New England Journal of Medicine (2016)

An analysis of data from Brazil reveals a strong association between the risk of microcephaly in a newborn and the risk of Zika virus infection during the mother's first trimester of pregnancy. The association in the second and third trimesters was negligible.
Problems in analyzing the comparative costs of private versus public psychiatric care
Authors: S S Sharfstein, C A Taube, I D Goldberg
Journal: American Journal of Psychiatry (1977)

The authors outline the difficulties in attempting to compare the costs of service in various mental health settings, especially private practice and community mental health centers. Contributing to the difficulties are the differences in the populations served, differences in treatment modalities employed, and the different economic incentives operating in each setting. The authors stress the need for research on cost effectiveness as the basis for valid comparisons of various care settings.
P0662 : 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials
Authors: M.J. Sonneveld, H.L. Chan, J. Cheng, T. Piratvisuth, J.-D. Jia, E. Gane, Y.-F. Liaw, B.E. Hansen, Q. Xie, V.W.-S. Wong, J.-L. Hou, H.L. Janssen
Journal: Journal of Hepatology (2015)
The pregnant psychotherapist in training: some preliminary findings and impressions
Authors: O E Baum, C Herring
Journal: American Journal of Psychiatry (1975)

With more women entering general medical and psychiatric training, the more that supervisors and staff can understand the impact of the resident's pregnancy on the resident and others, the more helpful they can be to her and she to herself. The authors' work was done at what was formerly the Woman's Medical College of Pennsylvania, which has had a larger percent of women in psychiatric training than most programs. This report is derived from a pilot study on the pregnant therapist.
The Viet Nam Era prisoner of war: precaptivity personality and the development of psychiatric illness
Authors: R J Ursano
Journal: American Journal of Psychiatry (1981)

The author examines the role of the preexisting personality structure in the development of psychiatric illness after prisoner of war (POW) experience using case studies of six repatriated Viet Nam POWs who were coincidentally evaluated before their captivity. Findings indicate that the presence of psychiatric illness or predisposition to psychiatric illness is neither necessary nor sufficient for the development of psychiatric illness after repatriation. Personality changes reflect both adaptation to the captivity environment and the impact of the ego-ideal over that of the punitive elements of the superego. The perspective of personality change rather than psychopathology is more explanatory of the findings.
Deoxyribosidic Compounds in Regenerating Liver
Authors: Walter C. Schneider, Leona W. Brownell
Journal: JNCI Journal of the National Cancer Institute (1957)

Deoxyribosidic Compounds in Regenerating Liver Get access Walter C. Schneider, Walter C. Schneider National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Leona W. Brownell Leona W. Brownell National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 4, April 1957, Pages 579–586, https://doi.org/10.1093/jnci/18.4.579 Published: 01 April 1957 Article history Published: 01 April 1957 Received: 13 December 1966
Memory deficits and anticholinergic levels in chronic schizophrenia
Authors: D Perlick, P Stastny, I Katz, M Mayer, S Mattis
Journal: American Journal of Psychiatry (1986)

Recent memory correlated inversely with serum anticholinergic levels for verbal recall but not for recognition memory in 17 chronic schizophrenic inpatients taking neuroleptic medications. The results indicate that anticholinergic activity does not impair primary memory functioning in chronic schizophrenia.
Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders.
Authors: Katerina Machova Polakova, Sylvie Nadvornikova, Karla Zemanova, Hana Klamova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Jiri Mayer, Marek Trneny, Jana Moravcova
Journal: Blood (2010)
A NOTE ON THE TESTING OF DISINFECTANTS
Authors: S. Rideal, J. T. A. Walker
Journal: BMJ (1915)

IN VIEW of the fact that the International Committee on The Standardization of Disinfectants, appointed at the last meeting of the International Congress on Applied Chemistry, cannot meet this year, owing to the war, and that this may entail a further delay of three years, we desire to call attention to one or two points which have arisen since the publication of our paper on Approved Technique of The Rideal-Walker Test, * and to submit the following suggestions as addenda to the paper referred to. First, in view of the difficulty experienced by some workers not familiar with the technique of the chemical laboratory, we sliggest that a burette, such as that described by Hermann W. Mahr, of the Board of Estimate and Apportionment, New York, pan be adopted in place of the dropping pipette. On the other hand, we know many workers who have a decided preference for the dropping pipette originally used by ourselve's and who do not see the necessity for changing this detail of the technique.
Case 25-1984
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Barry L. Fanburg, Nancy L. Harris, Eugene J. Mark
Journal: New England Journal of Medicine (1984)

Presentation of CaseA 74-year-old man was admitted to the hospital because of wheezing.There was a history of asthma since childhood, and a lengthy history of chronic obstructive pulmonary disease. The patient smoked cigarettes for approximately 25 years and discontinued smoking 10 years before entry. During the past 10 years he experienced no severe bouts of wheezing. He was otherwise well until four months before admission, when he was involved in a motor-vehicle accident and was brought to this hospital. Examination showed multiple facial lacerations and bilateral cervical lymphadenopathy. Wheezes were heard in both lungs. The edge of the . . .
Exophthalmos Response During Roentgen Therapy
Authors: R J BLAHUT, W H BEIERWALTES, I LAMPE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal